General
What is the percentage that breast cancer accounts for new cancer cases for women in the US
~30%
The prospective trial which offered predictive information on ER+, node -, HER2- women with Oncotype score <26
TAILORx
The other name for HER1
EGFR
Percentage breast cancer patients that have triple negative subtype
10-15%
The most common mutation that causes breast cancer (be specific)
BRCA1 mutation
Biomarkers that can be tested to determine HR+, HER2- subtype
PIK3CA/AKT1/PTEN and ESR1
Neratinib (Nerlynx) is a TKI that irreversible binds to which HER receptors
HER1, HER2, and HER4
What chemotherapy agents can be used in combo with pembrolizumab (Keytruda)
Paclitaxel (Abraxane)
Gemcitabine (Gemzar)+Carboplatin (Paraplatin)
What is the approximate 5 year survival rate for those diagnosed with breast cancer
~90%
When can Olaparib (Lynparza) be used after adjuvant chemo in HR+, HER-2 - breast cancer patients
= or > positive LN after chemo
What drug has shown superior CNS activity for untreated HER2+ brain mets in the HER2 CLIMB trial
tucatinib (Tukysa)
Antibody-drug conjugate that releases a topoisomerase inhibitor which can be used in any 2nd line metastatic TNBC
sacituzumab govitecan (Trodelvy)
What age should most women start screenings for breast cancer
40 years old
Sooner if family history or known genetic mutations such as BCRA
The indication for adjuvant abemaciclib (Verzenio)
HR+ HER2-, node+ breast cancer at high risk of recurrence and Ki-67 >20%
Preferred first-line chemotherapy regimen in metastatic HER2+ patients
docetaxel or paclitaxel + pertuzumab (Perjeta) + trastuzumab (Herceptin)
Which trial earned FDA approval for Pembro + chemo in neoadjuvant TNBC, regardless of PD-L1 expression
KEYNOTE 522
The subtype of breast cancer commonly associated with p53 mutation
HER2+
Which population has the SERD Elacestrant been approved for?
Metastatic ER+, HER2- with ESR1 mutation, previously treated with an AI
What is the drug:antibody ratio of trastuzumab-deruxtecan (Enhertu)
8:1
What drug had its approval withdrawn in 2021 for PD-L1+ metastatic TNBC due to lack of efficacy in clinical trials
Atezolizumab (Tecentriq)